14 Sept 2013: CTO, Mr Ung Eng Huan presented in the 25th Veterinary Association Congress (VAM) in Desaru, Malaysia.
4-6 Sept 2013: CTO, Mr. Ung Eng Huan presented and attended the APEC Conference on Biotechnology Commercialization organised by the Malaysian Biotechnology Corporation.
7 July 2013: Background IP entering into National Phase in USA, EU, Singapore, China, Malaysia, Korea, India and Australia
24-26 June 2013: CTO and Regulatory Officer attended Biosafety Training for Leaders organised by the Tropical Infectious Diseases Research and Education Centre (TIDREC).
25 June 2013: Three International (PCT) Applications filed: (1) Anticancer Treatment (2) Dosage Regime of Fusion Compounds (3) Rapid Specific Free Pathogen Animal.
18-19 June 2013: CTO, Mr. Ung Eng Huan participated in the Asian Orphan Drug Congress in Singapore.
30 May 2013: CTO, Mr. Ung Eng Huan presented in Aquatech 2014 in Philippines.
19-20 Mar 2013: Exhibited at the 6th Annual BioPharma Asia 2013, Singapore. Mr. Ung Eng Huan, CTO of BioValence presented on “RetroMAD1 ‘First-in-Class’ Broad-spectrum Oral Delivery Antiviral Protein”
10 Aug 2012: Received NPCB approval to build cGMP Facility for Phase I Clinical Batch Production.
12 Jul 2012: PCT Application for “ANTIMICROBIAL FUSION COMPOUNDS AND USES THEREOF” (PCT/MY2012/000003) was published on WIPO International. Read more at: http://patentscope.wipo.int